Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

psoriasis

- PMLiVE

Novartis’ Cosentyx off to a flyer in psoriasis

Year-to-date sales reach $140m for recently approved drug

- PMLiVE

Leo Pharma’s Enstilar approved by FDA

Topical psoriasistreatment given the green light

- PMLiVE

FDA turns down Pfizer’s Xeljanz in psoriasis

USregulator dampens the firm's hope of expanding arthritis drug's uses

Boehringer Ingelheim headquarters

Boehringer says anti-IL-23 drug beats Stelara in psoriasis trial

Interleukin-23 inhibitor outperforms Johnson & Johnson's blockbuster

- PMLiVE

Janssen launches Stelara in the UK for adolescents

Psoriasis drug now available for younger patients

- PMLiVE

Becoming a socially-active pharmaceutical company

A guest blog from LEO Pharma Spain on patient focus and its use of social networks

- PMLiVE

Celgene’s psoriasis pill gives ‘no added benefit’ to patients

Germany’s cost assessor IQWiG says Otezla is not value for money

Infographic: PsO market snapshot

An overview of the PsO biologic and systemic patientOur PsO market snapshot offers an introduction to the real world patient data collected by our Therapy Watch PsO study. The snapshot...

Research Partnership

- PMLiVE

Humira gets OK for childhood psoriasis in Europe

First biologic drug to be approved in the region for children as young as four

- PMLiVE

Boehringer to move psoriasis programme into phase III

Candidate outperformed J&J’s rival Stelara 

- PMLiVE

Stelara outlook promising for psoriatic arthritis

Likely to be recommended alone and in combination with methotrexate

- PMLiVE

Cosentyx has big impact on psoriasis, says Novartis

New data shows it to achieve clear or almost clear skin

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links